Detalhe da pesquisa
1.
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Cancer;
126(12): 2821-2828, 2020 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32154928
2.
Profiles of brain metastases: Prioritization of therapeutic targets.
Int J Cancer;
143(11): 3019-3026, 2018 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29923182
3.
Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.
J Neurooncol;
135(1): 75-81, 2017 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28702781
4.
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
J Neurooncol;
119(1): 135-40, 2014 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24803001
5.
Integrated phase II/III clinical trials in oncology: a case study.
Clin Trials;
9(6): 741-7, 2012 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23180870
6.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Neuro Oncol;
22(8): 1073-1113, 2020 08 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32328653
7.
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
Neuro Oncol;
17(2): 180-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25165194
8.
Clinical trial end points for high-grade glioma: the evolving landscape.
Neuro Oncol;
13(3): 353-61, 2011 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21310734